Evonik is making progress with the expansion of its DL-methionine production plant in Singapore. In order to reach an important milestone in the construction process, production at the Singapore plant on Jurong Island will be reduced for three months in Q4/2023, followed by another three-month tie-in shutdown in the first half of 2024.

This shutdown is part of the implementation of Evonik’s methionine asset strategy to safeguard long-term global supply security. The expansion is proceeding as expected and the planned production stops in Q4/2023 and H1/2024, which are necessary for maintenance and safety reasons, will allow modifications to be made that would not be possible during day-to-day operations.

“We fully understand that these shutdowns may pose challenges for our customers and our teams have prepared mitigation plans for MetAMINO® supply from our global production network. We are in continuous communication with regional and global customers to carefully plan shipments,” said Noel Kim, regional vice president Animal Nutrition.

Earlier this year, Evonik announced a high double-digit million-euro investment to boost the production capacity of MetAMINO® (DL-methionine) on Jurong Island, Singapore, by 40,000 metric tons per year to around 340,000 metric tons per year. The expansion will improve the efficiency of the facility’s processes and reduce the carbon footprint of all Evonik’s MetAMINO® production in Singapore by 6% (Scope 1+2+3).